A combined team of Biodexa Pharmaceuticals, Emtora Biosciences, LumaBridge, Precision for Medicine, and Pfizer is advancing eRapa for FAP treatment.
2 reports, 1 independent
Updated Aug 19
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A combined team of Biodexa Pharmaceuticals, Emtora Biosciences, LumaBridge, Precision for Medicine, and Pfizer is advancing eRapa for FAP treatment.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Biodexa, Emtora, and LumaBridge formed a collaboration to advance the Serenta trial, with the Cancer Prevention and Research Institute of Texas hosting the work.Sub-event
A combined team of Biodexa Pharmaceuticals, Emtora Biosciences, LumaBridge, Precision for Medicine, and Pfizer is advancing eRapa for FAP treatment.1 source
- Pfizer approved Rapamune (Rapamycin) for FAP treatment developed by Biodexa.
Keep exploring
The entities involved
-
Precision for Medicine (United States)
company in Frederick, United States
Nothing else this week.
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
Related events
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaFirst two subjects enrolled in Biodexa’s Phase III trial for FAP treatment Biodexa Pharmaceuticals has enrolled the initial two subjects in the placebo-controlled Phase III Serenta study of an oral c
- Unknown outlet